DURHAM, N.C., July 01, 2024 (GLOBE NEWSWIRE) -- Humacyte, Inc. (Nasdaq: HUMA), a clinical-stage biotechnology platform company developing universally implantable, bioengineered human tissues at ...
DURHAM, N.C., Feb. 26, 2025 (GLOBE NEWSWIRE) -- Humacyte, Inc., a commercial-stage biotechnology platform company developing universally implantable, bioengineered human tissues at commercial scale, ...
In a trial, an acellular tissue engineered vessel had superior functional patency for hemodialysis with acceptable safety compared with an arteriovenous fistula in high-risk patients. An acellular ...
Please provide your email address to receive an email when new articles are posted on . Symvess is a sterile, cell-free tissue engineered vessel made of human extracellular matrix proteins. Among 54 ...
SEATTLE--(BUSINESS WIRE)--Pluristyx, a leading provider of tools, technologies, and services for the development of cellular therapies, is pleased to announce a license agreement with Humacyte, Inc., ...
Humacyte (HUMA) announced the presentation of positive results from the V007 Phase 3 clinical trial of the acellular tissue engineered vessel, ATEV, in arteriovenous, AV, access for patients with ...
An investigational product called Acellular Tissue Engineered Vessel demonstrated superior hemodialysis vascular access outcomes compared with AVFs in a phase 3 trial. A bioengineered human tissue ...
DURHAM, N.C., Dec. 19, 2024 (GLOBE NEWSWIRE) -- Humacyte, Inc. (HUMA), a biotechnology platform company developing universally implantable, bioengineered human tissues at commercial scale, today ...
– SYMVESS is a first-in-class bioengineered human tissue designed to be a universally implantable vascular conduit for use in arterial replacement and repair – – In clinical testing SYMVESS was ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback